| Date: | 2023/10/11 |
|-----------------|--|
| Your Name:_ | Ping Huang |
| Manuscript T | itle:Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting |
| <u>stemness</u> | |
| Manuscript n | umber (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | _ | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | | | |
|-----|---|--------------------------|---------------|--|--|
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| _ | educational events | • | | | |
| 6 | Payment for expert | XNone | | | |
| | testimony | | | | |
| 7 | Company for appearation | V N | | | |
| / | Support for attending meetings and/or travel | _XNone | | | |
| | meetings and/or traver | | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | X None | | | |
| U | pending | X NONE | | | |
| | P | | | | |
| 9 | Participation on a Data | X None | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | XNone | | | |
| | in other board, society, | | | | |
| | committee or advocacy | | | | |
| 4.4 | group, paid or unpaid | •• | | | |
| 11 | Stock or stock options | XNone | | | |
| | | | | | |
| 12 | Receipt of equipment, | X None | | | |
| 12 | materials, drugs, medical writing, gifts or other | X NOTIE | | | |
| | | | | | |
| | services | | | | |
| 13 | Other financial or non- | XNone | | | |
| | financial interests | | | | |
| | | | | | |
| | | | | | |
| DI- | | fl: -4 - f :4 4 : 4 f- | Laurena harra | | |
| PIE | Please summarize the above conflict of interest in the following box: | | | | |
| | None | | | | |
| | None | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| Date: | 2023/10/11 |
|-----------------|--|
| Your Name:_ | Huachao Li |
| Manuscript 1 | itle:Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting |
| <u>stemness</u> | |
| Manuscript r | number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | | | |
|-----|--|--------------------------------|-------------|--|--|
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| c | educational events | V Name | | | |
| 6 | Payment for expert testimony | XNone | | | |
| | testimony | | | | |
| 7 | Support for attending | X None | | | |
| , | meetings and/or travel | _XNone | | | |
| | <i>5</i> , | | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | X None | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | XNone | | | |
| | in other board, society, | | | | |
| | committee or advocacy group, paid or unpaid | | | | |
| 11 | Stock or stock options | X None | | | |
| | Stock of Stock options | XNone | | | |
| | | | | | |
| 12 | Receipt of equipment, | X None | | | |
| | materials, drugs, medical | | | | |
| | writing, gifts or other | | | | |
| | services | •• | | | |
| 13 | Other financial or non- financial interests | X None | | | |
| | illidiicidi liiterests | | | | |
| | | | | | |
| | | | | | |
| Ple | ease summarize the above co | onflict of interest in the fol | lowing box: | | |
| _ | | | | | |
| | None | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| Date: | _2023/10/11 |
|-----------------|--|
| Your Name:_ | Liping Ren |
| Manuscript T | itle:Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting |
| <u>stemness</u> | |
| Manuscript n | umber (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | XNone | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) No time limit for this item. | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | X None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | X None | |
| | | | |
| | | | |
| 4 | Consulting fees | X None | |
| | | | |

| 5 | Payment or honoraria for | XNone | | | |
|-----|--|--------------------------------|-------------|--|--|
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| c | educational events | V Name | | | |
| 6 | Payment for expert testimony | XNone | | | |
| | testimony | | | | |
| 7 | Support for attending | X None | | | |
| , | meetings and/or travel | _XNone | | | |
| | <i>5</i> , | | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | X None | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | XNone | | | |
| | in other board, society, | | | | |
| | committee or advocacy group, paid or unpaid | | | | |
| 11 | Stock or stock options | X None | | | |
| | Stock of Stock options | XNone | | | |
| | | | | | |
| 12 | Receipt of equipment, | X None | | | |
| | materials, drugs, medical | | | | |
| | writing, gifts or other | | | | |
| | services | •• | | | |
| 13 | Other financial or non- financial interests | X None | | | |
| | illidiicidi liiterests | | | | |
| | | | | | |
| | | | | | |
| Ple | ease summarize the above co | onflict of interest in the fol | lowing box: | | |
| _ | | | | | |
| | None | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| Date: | _2023/10/11 |
|-----------------|--|
| Your Name:_ | Haimei Xie |
| Manuscript T | itle:Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting |
| <u>stemness</u> | |
| Manuscript r | umber (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Time frame: Since the initialXNone | pranning of the work |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | | | |
|-----|--|--------------------------------|-------------|--|--|
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| c | educational events | V Name | | | |
| 6 | Payment for expert testimony | XNone | | | |
| | testimony | | | | |
| 7 | Support for attending | X None | | | |
| , | meetings and/or travel | _XNone | | | |
| | <i>5</i> , | | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | X None | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | XNone | | | |
| | in other board, society, | | | | |
| | committee or advocacy group, paid or unpaid | | | | |
| 11 | Stock or stock options | X None | | | |
| | Stock of Stock options | XNone | | | |
| | | | | | |
| 12 | Receipt of equipment, | X None | | | |
| | materials, drugs, medical | | | | |
| | writing, gifts or other | | | | |
| | services | •• | | | |
| 13 | Other financial or non- financial interests | X None | | | |
| | illidiicidi liiterests | | | | |
| | | | | | |
| | | | | | |
| Ple | ease summarize the above co | onflict of interest in the fol | lowing box: | | |
| _ | | | | | |
| | None | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| Date: | _2023/10/11 |
|-----------------|--|
| Your Name:_ | Liushan Chen |
| Manuscript T | itle:Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting |
| <u>stemness</u> | |
| Manuscript n | umber (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | _ | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | | | |
|-----|--|--------------------------------|-------------|--|--|
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| c | educational events | V Name | | | |
| 6 | Payment for expert testimony | XNone | | | |
| | testimony | | | | |
| 7 | Support for attending | X None | | | |
| , | meetings and/or travel | _XNone | | | |
| | <i>5</i> , | | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | X None | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | XNone | | | |
| | in other board, society, | | | | |
| | committee or advocacy group, paid or unpaid | | | | |
| 11 | Stock or stock options | X None | | | |
| | Stock of Stock options | XNone | | | |
| | | | | | |
| 12 | Receipt of equipment, | X None | | | |
| | materials, drugs, medical | | | | |
| | writing, gifts or other | | | | |
| | services | •• | | | |
| 13 | Other financial or non- financial interests | X None | | | |
| | illidiicidi liiterests | | | | |
| | | | | | |
| | | | | | |
| Ple | ease summarize the above co | onflict of interest in the fol | lowing box: | | |
| _ | | | | | |
| | None | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| Date: | _2023/10/11 |
|-----------------|--|
| Your Name:_ | Yuqi Liang |
| Manuscript T | itle:Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting |
| <u>stemness</u> | |
| Manuscript n | umber (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | | | |
|-----|--|--------------------------------|-------------|--|--|
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| c | educational events | V Name | | | |
| 6 | Payment for expert testimony | XNone | | | |
| | testimony | | | | |
| 7 | Support for attending | X None | | | |
| , | meetings and/or travel | _XNone | | | |
| | <i>5</i> , | | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | X None | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | XNone | | | |
| | in other board, society, | | | | |
| | committee or advocacy group, paid or unpaid | | | | |
| 11 | Stock or stock options | X None | | | |
| | Stock of Stock options | XNone | | | |
| | | | | | |
| 12 | Receipt of equipment, | X None | | | |
| | materials, drugs, medical | | | | |
| | writing, gifts or other | | | | |
| | services | •• | | | |
| 13 | Other financial or non- financial interests | X None | | | |
| | illidiicidi liiterests | | | | |
| | | | | | |
| | | | | | |
| Ple | ease summarize the above co | onflict of interest in the fol | lowing box: | | |
| _ | | | | | |
| | None | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| Date: | 2023/10/11 |
|-----------------|---|
| Your Name:_ | Yuyu Hu |
| Manuscript 1 | tle:Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting |
| <u>stemness</u> | |
| Manuscript i | umber (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | _ | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | | | |
|-----|--|--------------------------------|-------------|--|--|
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| c | educational events | V Name | | | |
| 6 | Payment for expert testimony | XNone | | | |
| | testimony | | | | |
| 7 | Support for attending | X None | | | |
| , | meetings and/or travel | _XNone | | | |
| | <i>5</i> , | | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | X None | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | XNone | | | |
| | in other board, society, | | | | |
| | committee or advocacy group, paid or unpaid | | | | |
| 11 | Stock or stock options | X None | | | |
| | Stock of Stock options | XNone | | | |
| | | | | | |
| 12 | Receipt of equipment, | X None | | | |
| | materials, drugs, medical | | | | |
| | writing, gifts or other | | | | |
| | services | •• | | | |
| 13 | Other financial or non- financial interests | X None | | | |
| | illidiicidi liiterests | | | | |
| | | | | | |
| | | | | | |
| Ple | ease summarize the above co | onflict of interest in the fol | lowing box: | | |
| _ | | | | | |
| | None | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| Date: September 20, 2023 |
|---|
| Your Name: Heloisa Sobreiro Selistre-de-Araujo |
| Manuscript Title: Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting |
| stemness |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | _ | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | | | |
|------------|---|-------|--|--|--|
| | lectures, presentations, | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| | educational events | | | | |
| 6 | Payment for expert | XNone | | | |
| | testimony | | | | |
| | - | | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | XNone | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | XNone | | | |
| | in other board, society, | | | | |
| | committee or advocacy | | | | |
| | group, paid or unpaid | | | | |
| 11 | Stock or stock options | XNone | | | |
| | | | | | |
| | | | | | |
| 12 | Receipt of equipment, | XNone | | | |
| | materials, drugs, medical | | | | |
| | writing, gifts or other | | | | |
| | services | | | | |
| 13 | Other financial or non- | XNone | | | |
| | financial interests | | | | |
| | | | | | |
| | | | | | |
| 6 1 | | | | | |
| PIE | Please summarize the above conflict of interest in the following box: | | | | |
| | None | | | | |
| | None. | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| Date: 18 September 2023 |
|---|
| Your Name: Stergios Boussios |
| Manuscript Title: Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting |
| stemness |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | T | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article processing charges, etc.) | | |
| | No time limit for this item. | | |
| | No time illint for this item. | | |
| | | | |
| | | · | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |
| | | | |

| 5 | Payment or honoraria for | None | |
|----|--|------|--|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | None | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | in other board, society, committee or advocacy | None | |
| | | | |
| | | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | None | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |

Please summarize the above conflict of interest in the following box:

| None | | |
|------|--|--|
| | | |
| | | |
| | | |

Please place an "X" next to the following statement to indicate your agreement:

| Date: 9/ | /24/23 |
|----------|--------|
|----------|--------|

Your Name: Sachin Jhawar

Manuscript Title: Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting

stemness

| Manuscript number | (if known): | | | |
|-------------------|--------------|--|------|--|
| Manuscript number | (if known):_ | | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | XNone | |
| | manuscript (e.g., funding, provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | Varian Medical Systems | Grant to study the oropharyngeal microbiome in HNC patients |
| | in item #1 above). | | |
| | | | |
| 3 | Royalties or licenses | _XNone | |
| | | | |
| | | | |
| 4 | Consulting fees | Enlace health | Consulting fees to consult on radiation oncology |

| | | | payment models for insurance companies |
|----|---|--------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | XNone | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | XNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | Leadership or fiduciary role | X None | |
| 10 | in other board, society, | XNone | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | XNone | |
| | materials, drugs, medical writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | XNone | |
| | financial interests | | |
| | | | |
| | | | |

Please summarize the above conflict of interest in the following box:

Dr. Jhawar reports grant from Varian Medical Systems to study the oropharyngeal microbiome in HNC patients, and consulting fees from Enlace health to consult on radiation oncology payment models for insurance companies.

Please place an "X" next to the following statement to indicate your agreement:

| Date: | _2023/10/11 |
|-----------------|--|
| Your Name:_ | Rutao Cui |
| Manuscript T | itle:Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting |
| <u>stemness</u> | |
| Manuscript n | umber (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Time frame: Since the initialXNone | pranning of the work |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for | XNone | | |
|-----|--|--------------------------------|-------------|--|
| | lectures, presentations, | | | |
| | speakers bureaus, | | | |
| | manuscript writing or | | | |
| c | educational events | V Name | | |
| 6 | Payment for expert testimony | XNone | | |
| | testimony | | | |
| 7 | Support for attending | X None | | |
| , | meetings and/or travel | _XNone | | |
| | <i>5</i> , | | | |
| | | | | |
| | | | | |
| 8 | Patents planned, issued or | X None | | |
| | pending | | | |
| | | | | |
| 9 | Participation on a Data | XNone | | |
| | Safety Monitoring Board or | | | |
| | Advisory Board | | | |
| 10 | Leadership or fiduciary role | XNone | | |
| | in other board, society, | | | |
| | committee or advocacy group, paid or unpaid | | | |
| 11 | Stock or stock options | X None | | |
| | Stock of Stock options | XNone | | |
| | | | | |
| 12 | Receipt of equipment, | X None | | |
| | materials, drugs, medical | | | |
| | writing, gifts or other | | | |
| | services | •• | | |
| 13 | Other financial or non- financial interests | X None | | |
| | illidiicidi liiterests | | | |
| | | | | |
| | | | | |
| Ple | ease summarize the above co | onflict of interest in the fol | lowing box: | |
| _ | | | | |
| | None | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| Date: | _2023/10/11 |
|-----------------|--|
| Your Name:_ | Qian Zuo |
| Manuscript T | itle:Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting |
| <u>stemness</u> | |
| Manuscript n | number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | | |
|---|---|--|---|--|--|
| | Time frame: Since the initial planning of the work | | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | | | |
| | | Time frame: past | 36 months | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | | | |
| 3 | Royalties or licenses | XNone | | | |
| 4 | Consulting fees | XNone | | | |

| 5 I | lectures, presentations, | XNone | | | |
|-----|---|---------------|--|--|--|
| | | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| c | educational events | V Name | | | |
| 6 | Payment for expert testimony | XNone | | | |
| | testimony | | | | |
| 7 | Support for attending | X None | | | |
| , | meetings and/or travel | _XNone | | | |
| | <i>5</i> , | | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | X None | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | X None | | | |
| | in other board, society, | | | | |
| | committee or advocacy group, paid or unpaid | | | | |
| 11 | Stock or stock options | X None | | | |
| | Stock of Stock options | XNone | | | |
| | | | | | |
| 12 | Receipt of equipment, | XNone | | | |
| | materials, drugs, medical | | | | |
| | writing, gifts or other | | | | |
| 42 | services | v | | | |
| 13 | Other financial or non- financial interests | XNone | | | |
| | illialiciai liiterests | | | | |
| | | | | | |
| | | | | | |
| Ple | Please summarize the above conflict of interest in the following box: | | | | |
| | | | | | |
| | None | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| Date: | _2023/10/11 |
|-----------------|--|
| Your Name:_ | Qianjun Chen |
| Manuscript T | itle:Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting |
| <u>stemness</u> | |
| Manuscript n | umber (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 I | lectures, presentations, | XNone | | | |
|-----|---|---------------|--|--|--|
| | | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| c | educational events | V Name | | | |
| 6 | Payment for expert testimony | XNone | | | |
| | testimony | | | | |
| 7 | Support for attending | X None | | | |
| , | meetings and/or travel | _XNone | | | |
| | <i>5</i> , | | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | X None | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role | X None | | | |
| | in other board, society, | | | | |
| | committee or advocacy group, paid or unpaid | | | | |
| 11 | Stock or stock options | X None | | | |
| | Stock of Stock options | XNone | | | |
| | | | | | |
| 12 | Receipt of equipment, | XNone | | | |
| | materials, drugs, medical | | | | |
| | writing, gifts or other | | | | |
| 42 | services | v | | | |
| 13 | Other financial or non- financial interests | XNone | | | |
| | illialiciai liiterests | | | | |
| | | | | | |
| | | | | | |
| Ple | Please summarize the above conflict of interest in the following box: | | | | |
| | | | | | |
| | None | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |